share_log
Moomoo 24/7 ·  Apr 4 10:50
ADC Therapeutics Shares Are Trading Higher. The Company Announced the Completion of Dose Escalation in LOTIS-7, a Phase 1b Open-label Clinical Trial Evaluating ZYNLONTA in Combination With Glofitamab or Mosunetuzumab in Heavily Pre-treated Patients With Relapsed/refractory B-cell Non-Hodgkin Lymphoma
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment